WO1994029333A1 - Reactifs immunoreactifs utilisant la monoamine-oxydase - Google Patents

Reactifs immunoreactifs utilisant la monoamine-oxydase Download PDF

Info

Publication number
WO1994029333A1
WO1994029333A1 PCT/US1994/006424 US9406424W WO9429333A1 WO 1994029333 A1 WO1994029333 A1 WO 1994029333A1 US 9406424 W US9406424 W US 9406424W WO 9429333 A1 WO9429333 A1 WO 9429333A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
reagent
residue
mao
monoamine oxidase
Prior art date
Application number
PCT/US1994/006424
Other languages
English (en)
Inventor
Christopher D. V. Black
Robert Allen Snow
Original Assignee
The Wellcome Foundation Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Wellcome Foundation Limited filed Critical The Wellcome Foundation Limited
Priority to AU72448/94A priority Critical patent/AU7244894A/en
Priority to JP7502055A priority patent/JPH09501147A/ja
Priority to EP94921934A priority patent/EP0710244A1/fr
Publication of WO1994029333A1 publication Critical patent/WO1994029333A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0014—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4)
    • C12N9/0022—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Dans une variante, cette invention concerne un immunoréactif de ciblage non radioactif comprenant le résidu d'un site actif protéique d'une enzyme monoamine-oxydase (MAO), un groupe de liaison, et le résidu d'un matériau immunoréactif ainsi qu'un agent d'administration radioactif comprenant un liant spécifique à cette fraction du récepteur de MAO, un groupe de liaison et un agent radioactif. Dans une autre variante, cette invention concerne un immunoréactif de ciblage non radioactif comprenant le résidu d'un liant spécifique à une fraction réceptrice du site actif protéique de MAO, un groupe de liaison, et le résidu d'un matériau immunoréactif ainsi qu'un agent d'administration radioactif comprenant le résidu d'une fraction réceptrice du site actif protéique de MAO, un groupe de liaison et un agent radioactif. Ces compositions comprennent des systèmes utiles dans la production d'une amplification de l'administration de l'agent radioactif sur des sites tumoraux dans l'imagerie thérapeutique et de diagnostic du cancer.
PCT/US1994/006424 1993-06-07 1994-06-07 Reactifs immunoreactifs utilisant la monoamine-oxydase WO1994029333A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU72448/94A AU7244894A (en) 1993-06-07 1994-06-07 Immunoreactive reagents employing monoamine oxidase
JP7502055A JPH09501147A (ja) 1993-06-07 1994-06-07 モノアミンオキシダーゼを使用する免疫反応性試薬
EP94921934A EP0710244A1 (fr) 1993-06-07 1994-06-07 Reactifs immunoreactifs utilisant la monoamine-oxydase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7319893A 1993-06-07 1993-06-07
US08/073,198 1993-06-07

Publications (1)

Publication Number Publication Date
WO1994029333A1 true WO1994029333A1 (fr) 1994-12-22

Family

ID=22112332

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/006424 WO1994029333A1 (fr) 1993-06-07 1994-06-07 Reactifs immunoreactifs utilisant la monoamine-oxydase

Country Status (5)

Country Link
EP (1) EP0710244A1 (fr)
JP (1) JPH09501147A (fr)
AU (1) AU7244894A (fr)
CA (1) CA2164518A1 (fr)
WO (1) WO1994029333A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014145A2 (fr) * 2001-08-10 2003-02-20 Novartis Ag Peptides se liant avec les lesions atherosclereuses
WO2007088051A2 (fr) 2006-01-31 2007-08-09 Bayer Schering Pharma Aktiengesellschaft Modulation de l'activite mdl-1 pour le traitement de maladies inflammatoires
EP2072060A1 (fr) 2007-12-18 2009-06-24 Institut Curie Procédés et compositions pour la préparation et l'utilisation de conjugués de toxines
EP2514442A2 (fr) 2007-06-22 2012-10-24 mivenion GmbH Diagnostics d'imagerie par combinaison d'agents de contraste
WO2013151584A1 (fr) * 2011-10-31 2013-10-10 The Methodist Hospital Research Institute Composé comprenant un fragment de ciblage/recherche de mao pour le traitement de gliomes humains

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008297203A (ja) * 2007-05-29 2008-12-11 Chisso Corp 複合体

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4719182A (en) * 1985-03-18 1988-01-12 Eastman Kodak Company Fluorescent labels and labeled species and their use in analytical elements and determinations
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
US4913891A (en) * 1986-04-17 1990-04-03 The United States Of America As Represented By The United States Department Of Energy Positron emitter labeled enzyme inhibitors
WO1992008494A2 (fr) * 1990-11-08 1992-05-29 Sterling Winthrop Inc. Immunoreactifs de ciblage radioactifs
US5254329A (en) * 1991-03-11 1993-10-19 Keiner Melvyn H Method for improving visualization of serotonergic structures in nonhuman vertebrates

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4719182A (en) * 1985-03-18 1988-01-12 Eastman Kodak Company Fluorescent labels and labeled species and their use in analytical elements and determinations
US4913891A (en) * 1986-04-17 1990-04-03 The United States Of America As Represented By The United States Department Of Energy Positron emitter labeled enzyme inhibitors
US4863713A (en) * 1986-06-23 1989-09-05 The Board Of Trustees Of Leland Stanford Jr. Univ. Method and system for administering therapeutic and diagnostic agents
WO1992008494A2 (fr) * 1990-11-08 1992-05-29 Sterling Winthrop Inc. Immunoreactifs de ciblage radioactifs
US5254329A (en) * 1991-03-11 1993-10-19 Keiner Melvyn H Method for improving visualization of serotonergic structures in nonhuman vertebrates

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003014145A3 (fr) * 2001-08-10 2003-12-04 Novartis Ag Peptides se liant avec les lesions atherosclereuses
WO2003014145A2 (fr) * 2001-08-10 2003-02-20 Novartis Ag Peptides se liant avec les lesions atherosclereuses
WO2007088051A2 (fr) 2006-01-31 2007-08-09 Bayer Schering Pharma Aktiengesellschaft Modulation de l'activite mdl-1 pour le traitement de maladies inflammatoires
EP2907526A1 (fr) 2007-06-22 2015-08-19 mivenion GmbH Diagnostics d'imagerie par combinaison d'agents de contraste
EP2514442A2 (fr) 2007-06-22 2012-10-24 mivenion GmbH Diagnostics d'imagerie par combinaison d'agents de contraste
EP2572735A1 (fr) 2007-06-22 2013-03-27 mivenion GmbH Diagnostics d'imagerie par combinaison d'agents de contraste
EP2647392A2 (fr) 2007-06-22 2013-10-09 mivenion GmbH Diagnostics d'imagerie par combinaison d'agents de contraste
EP2072060A1 (fr) 2007-12-18 2009-06-24 Institut Curie Procédés et compositions pour la préparation et l'utilisation de conjugués de toxines
CN104136026A (zh) * 2011-10-31 2014-11-05 卫理公会医院研究所 包含mao靶向/探寻器部分的人神经胶质瘤治疗用化合物
KR20140128943A (ko) * 2011-10-31 2014-11-06 더 메서디스트 하스피틀 리서치 인스티튜트 인간의 신경교종을 치료하기 위한 모노아마이드 옥시다아제(Monoamide oxidase,MAO) 타겟팅/시커(seeker) 부분(moiety)을 포함하는 조성물
WO2013151584A1 (fr) * 2011-10-31 2013-10-10 The Methodist Hospital Research Institute Composé comprenant un fragment de ciblage/recherche de mao pour le traitement de gliomes humains
CN104136026B (zh) * 2011-10-31 2018-03-02 卫理公会医院研究所 包含mao靶向/探寻器部分的人神经胶质瘤治疗用化合物
US10555936B2 (en) 2011-10-31 2020-02-11 The Methodist Hospital Chemotherapeutic compositions and methods for treating human gliomas
KR102110794B1 (ko) 2011-10-31 2020-05-15 더 메서디스트 하스피틀 리서치 인스티튜트 인간의 신경교종을 치료하기 위한 모노아마이드 옥시다아제(Monoamide oxidase,MAO) 타겟팅/시커(seeker) 부분(moiety)을 포함하는 조성물
EP3815685A3 (fr) * 2011-10-31 2021-10-13 The Methodist Hospital Research Institute Composé comprenant un fragment de ciblage/recherche de mao pour le traitement de gliomes humains

Also Published As

Publication number Publication date
AU7244894A (en) 1995-01-03
CA2164518A1 (fr) 1994-12-22
JPH09501147A (ja) 1997-02-04
EP0710244A1 (fr) 1996-05-08

Similar Documents

Publication Publication Date Title
EP0173629B1 (fr) Complexes d'ions métalliques conjugés avec des anticorps
US4741900A (en) Antibody-metal ion complexes
Morais et al. Site-specific chelator-antibody conjugation for PET and SPECT imaging with radiometals
US5807879A (en) Biotinidase-resistant biotinylated compound and methods of use thereof
US5171563A (en) Cleavable linkers for the reduction of non-target organ retention of immunoconjugates
EP0207557B1 (fr) Macromolécules dérivées de diphosphonate
JPH10501531A (ja) モノアミン、ジアミド、チオール含有金属キレート剤
JPH05502236A (ja) 感染性及び炎症性病変の検出及び治療のためのキメラ抗体
US5217704A (en) Methods and materials for the preparation of metal labelled antibody solutions
JP3074160B2 (ja) 悪性腫瘍用画像化剤
CA2150477A1 (fr) Ciblage sequentiel des sites tumoraux a l'aide de conjugues oligonucleotidiques d'anticorps et de conjugues oligonucleotidiques complementaires de radionucleides chelates
WO1994029333A1 (fr) Reactifs immunoreactifs utilisant la monoamine-oxydase
EP0675737A1 (fr) Reactifs a reactivite immunologique utilisant la dihydrofolate reductase
EP0436664B1 (fr) Elements de liaison clivables pour la reduction de la retention d'immunoconjugues par des organes non cibles
CA2113578A1 (fr) Composes trifonctionnels specifiques de cellules multiresistantes
CN100457192C (zh) 生物素的氨基衍生物及其与大环螯合剂的结合物
JP2000503301A (ja) 減少した正味の正電荷を有する抗体
JPH05500953A (ja) 免疫共役体およびその代謝物の非標的保持量を減少させる方法
AU6128694A (en) Immunoreactive reagents employing heterodimers
EP4230637A1 (fr) Complexes radioactifs d'anticorps anti-her2 et produit radiopharmaceutique
MXPA98005565A (en) Antibodies with positive reduced load

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994921934

Country of ref document: EP

ENP Entry into the national phase

Ref country code: US

Ref document number: 1995 571852

Date of ref document: 19951205

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: CA

Ref document number: 2164518

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2164518

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 1994921934

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994921934

Country of ref document: EP